Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tayu Huaxia Biotech Medical Group Co. Ltd. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This application is under the review of 1 distinct examiner within 1 distinct art unit, indicating a highly concentrated prosecution focus. In the specialized fields of biotechnology and pharmaceuticals, such a narrow distribution means that the company's current patent efforts are centralized under a single technical authority. This structure allows for a direct dialogue with the patent office but also places the outcome of the 1 pending office action on the discretion of one individual.
The busiest examiner for this portfolio is OUSPENSKI, ILIA I, who is responsible for 1 pending office action. As there is only 1 distinct examiner involved in the company's current filings, OUSPENSKI, ILIA I oversees the entire active portfolio. For a practitioner, this concentration requires a deep understanding of this specific examiner's past rulings and technical preferences. The fact that the 1 pending office action is contained within 1 distinct art unit suggests that the subject matter is tightly focused within a specific technical niche at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18493568 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18493568 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | OUSPENSKI, ILIA I | 1644 | DP | Non-Final OA | — | Pending | Oct 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTayu Huaxia Biotech Medical Group Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ilia I Ouspenski has the most, with 1 of Tayu Huaxia Biotech Medical Group Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
